It's a post in a time warp - a rear vision mirror view of SBN's future.
If SBN only had Oraline iv in its portfolio - and it was heading into the future with just that - I would agree with you, and Serpie. In that circumstance, his analysis is apt and the large contracts he refers to would have to be secured to ensure survival.
But his analysis completerly ignores all the pipeline projects slated to come to fruition in the next half, many in the next quarter. He needs to be putting some figures on the contributions of the new urine devices (still 85% of the US $1b+ testing market), Oraline 8, roadside testing (now flagged on the web site) and particularly the SiYi joint venture and the Russia/Medinat partnership.
And no Irp, I'm not just into 'extreme positivity'. I can handle negativity if it comes my way. I was just as appalled as everyone by the FDA setback and am frustrated by the more recent Chairman's report re sales. But if negativity is not, in my view, supported by the facts, I will be inclined to point that out.
SBN Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
